Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4x Discry Hdgs Regulatory News (C4XD)

Share Price Information for C4x Discry Hdgs (C4XD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.00
Bid: 9.30
Ask: 9.98
Change: 0.00 (0.00%)
Spread: 0.68 (7.312%)
Open: 10.00
High: 0.00
Low: 0.00
Prev. Close: 10.00
C4XD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

17 Apr 2018 07:00

RNS Number : 0995L
C4X Discovery Holdings PLC
17 April 2018
 

This announcement contains inside information

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

PDMR Shareholdings

 

17 April 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that Dr Clive Dix, Chief Executive Officer, yesterday purchased 20,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 101.5 pence per Ordinary Share (the "Dealing"). Following the Dealing, Dr Clive Dix holds 1,344,936 Ordinary Shares, which represents an interest in 2.89% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Dr Clive Dix

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

1p ordinary shares

 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s) per Ordinary Share

Volume(s)

101.5p

20,000

e)

Date of the transaction

 

16 April 2018

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.

--ENDS-

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865 803

 

Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal 0203 709 5700

 

 

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline in inflammation, neurodegeneration, immuno-oncology, addiction, and diabetes with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets C4X Discovery will focus on the high-value disease areas and will continue to maximise value from opportunistic areas, for example, immuno-oncology, addiction, and diabetes.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAFLKFAKPEAF
Date   Source Headline
27th Mar 20247:00 amRNSProposed Voluntary Delisting
27th Mar 20247:00 amRNSInterim results
23rd Jan 20241:57 pmRNSResult of AGM
18th Jan 20247:00 amRNSBoard Update
4th Jan 20242:45 pmRNSHolding(s) in Company
3rd Jan 20247:00 amRNSAstraZeneca $11m milestone payment to C4XD
18th Dec 20233:31 pmRNSPosting of 2023 Annual Report and Notice of AGM
14th Dec 20237:00 amRNSFull Year Results
7th Dec 20237:00 amRNSNotice of Results
5th Oct 20232:35 pmRNSHolding(s) in Company
2nd Oct 202312:36 pmRNSBlock listing Interim Review
29th Sep 202311:14 amRNSGrant of Options and Directors Dealing
28th Sep 20233:52 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSTotal Voting Rights
18th Aug 202312:45 pmRNSExercise of Options, Issue of Equity and TVR
1st Aug 20237:00 amRNSDivestment of Orexin-1 to Indivior for £15.95m
20th Jun 20237:00 amRNSC4X Discovery Holdings plc: Board Change
1st Jun 20237:00 amRNSMALT-1 Inhibitor Programme Update
26th Apr 20237:00 amRNSHalf Year Results
19th Apr 20237:00 amRNSNotice of Results
8th Mar 20232:49 pmRNSBlock Listing Interim Review
22nd Feb 20237:00 amRNSC4XD and Garvan Institute collaboration
24th Jan 202311:47 amRNSResult of AGM
19th Jan 20237:00 amRNSMALT-1 Inhibitor Programme Update
10th Jan 20237:00 amRNSNick Ray Appointed as Chief Scientific Officer
19th Dec 20224:52 pmRNSPosting of 2022 Annual Report and Notice of AGM
15th Dec 20227:00 amRNSFull Year Results
28th Nov 20222:31 pmEQSC4X Discovery signs potential $402mln deal
28th Nov 20229:00 amRNSNotice of Final Results
28th Nov 20227:00 amRNSC4XD Agreement with AstraZeneca
1st Nov 20222:03 pmRNSExercise of Options, Issue of Equity and TVR
20th Oct 20227:00 amRNSC4XD and HitGen to collaborate in inflammation
4th Oct 20222:56 pmRNSHolding(s) in Company
22nd Sep 20224:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:35 pmRNSPrice Monitoring Extension
31st Aug 202211:10 amRNSHolding(s) in Company
17th Aug 20224:06 pmRNSHolding(s) in Company
17th Aug 20223:43 pmRNSHolding(s) in Company
16th Aug 20222:17 pmRNSHolding(s) in Company
11th Aug 202212:43 pmRNSResult of Placing to Raise £5.7 million
11th Aug 20227:00 amRNSProposed Placing to Raise Up To £5.7 million
2nd Aug 20227:00 amRNSBusiness Update
1st Aug 20223:09 pmRNSBlock Listing Interim Review
6th Jul 20227:00 amRNSC4X Discovery receives Sanofi milestone payment
28th Jun 20225:46 pmRNSAIM Rule 17 Schedule 2(g) Update
28th Apr 20227:00 amRNSHalf Year Results
19th Apr 20227:00 amRNSNotice of Results
28th Feb 20225:30 pmRNSExercise of Options, Issue of Equity and TVR
3rd Feb 20227:00 amRNSGrant of Options and Directors Dealing
1st Feb 20227:00 amRNSBlock listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.